FAQ: Your Compounded GLP-1 Questions, Answered

Who is actually allowed to make a compounded GLP-1?

A licensed pharmacy, working from a prescription written for you by a licensed clinician. This is not a back-room operation. State boards of pharmacy regulate these pharmacies, and the prescription has to name a real patient with a real clinical reason. The clinician evaluates you first. The pharmacy then prepares the medication to that order. No part of that is the patient deciding on their own.

The piece people miss is that "compounded" is not one thing. There are two legal lanes, and they answer to different rules. Almost every confusing headline you have seen lives in the gap between them.

Why does the 503A versus 503B difference matter to me?

Because the rules that make news usually apply to one lane and not the other. A 503A pharmacy prepares your medication under a prescription written for you specifically. A 503B outsourcing facility makes medications in larger volumes, often to stock a clinic, not always tied to one named patient. When a regulator changes something about 503B bulk supply, that does not automatically apply to a 503A pharmacy filling your individual prescription.

So when you read a scary headline, the first question is which lane it describes. If the answer is 503B and your treatment runs through a 503A pharmacy filling a prescription for you, the headline and your situation may be two different stories.

What did the FDA actually propose in 2026?

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances ¹. The agency had earlier declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025 ². Public comment on the proposal closed July 30, 2026, after a 30-day extension ¹.

Read the scope carefully. That proposal is about the 503B outsourcing lane and the bulk substances those facilities may keep on hand. It does not, on its face, change 503A pharmacies preparing a medication under a patient-specific prescription. The 503A lane has its own limits: a 503A pharmacy may not regularly make essentially copies of a commercially available drug unless a prescriber documents a change that produces a significant difference for that patient ². That distinction is the whole reason the headlines feel scarier than the situation often is for an individual patient.

Is a compounded GLP-1 safe?

Safety comes down to oversight, not the word "compounded." A medication prepared by a properly licensed pharmacy, under a prescription from a clinician who evaluated you and follows up, sits inside a real system of accountability. The risk rises sharply when people buy "research" vials online from sources with no pharmacy license, no prescription, and no clinician. Those are not compounded medications in the legal sense at all. Keep in mind that compounded drugs are not FDA approved, which means the FDA does not review them for safety, effectiveness or quality before they are marketed ³. Your physician and a licensed pharmacy are the safety system. Skipping them is the danger.

Why is compounded sometimes priced differently than branded?

Because it is a different kind of product, made a different way. A branded GLP-1 is a mass-manufactured, sealed product with its own supply chain and list price. A compounded preparation is made by a pharmacy to a prescription. The economics are not the same, so the prices are not the same. None of that makes one a version of the other. They are distinct products under distinct rules.

What should worry you is not the number itself. It is a number you cannot fully see. If a recurring price shows up anywhere in a provider's flow, that provider should disclose all of it before your card is charged. You should be able to read, in writing and before paying, the full monthly cost, any other fee, the recurring charge, and how to cancel. Recurring monthly charge until canceled. Cancel anytime in your account. No phone call required. Full cost disclosed before checkout.

Compounded versus branded, at a glance

This table compares categories, not specific results. It does not claim either product equals the other. Your clinician decides what is appropriate. Individual results vary.

A good GLP-1 provider tells you exactly where your medication is prepared and under what license. It shows you the full monthly cost, any other fee, the recurring charge, and the cancellation policy before your card is ever touched. It keeps a real clinician available for the weeks after the prescription, not just the moment of sale. And it never markets a compounded preparation as a generic of a brand or as the same thing as a branded drug, because a careful provider does not blur that line.

If a brand cannot give you all of that up front, walk away. That clarity is the standard a patient should demand. This is the standard sipra is built around. Nothing is charged until a physician approves, and the full cost is disclosed before checkout.

The confusion clears once you know which lane you are in and who is accountable for it. Here is where to start.

1. Ask which compounding lane your medication comes from. A provider should tell you plainly whether your GLP-1 is prepared by a state-licensed 503A pharmacy under a prescription written for you. If they dodge the question, that is information too.
2. Get the full cost in writing before you pay. The full monthly cost, any other fee, the recurring charge, and how to cancel. All of it, before your card is touched.
3. Pick a provider that stays after the prescription. Compounded or branded, the care around the medication matters as much as the medication. For why that standard matters, see how to vet a telehealth GLP-1 provider.